keyword
MENU ▼
Read by QxMD icon Read
search

Atorvastatin

keyword
https://www.readbyqxmd.com/read/28650330/evaluation-of-hypocholesterolemic-activity-of-extracts-of-bidens-odorata-and-brickellia-eupatorioides
#1
Diana Patricia Moreno Pena, Paula Cordero Pérez, Catalina Leos Rivas, Leticia Bucio, Jose Ezequiel Viveros Valdez, Linda Elsa Munoz Espinosa, Sagrcr Morales
We sought to evaluate the hypolipidemic activity of extracts of Bidens odorata and Brickellia eupatorioides using a model of hyperlipidemia induced in rats by Triton WR-1339 (300mg/kg intraperitoneally). The rats were divided into 5 groups of 3 rats each: normal control group, hyperlipidemic control group, hyperlipidemic with 20 mg/kg atorvastatin, hyperlipidemic with 300 mg/kg B. odorata extract, and hyperlipidemic with 300mg/kg B. eupatorioides extract, respectively. After 10 d of treatment by intragastric administration, the extract of B...
March 2017: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28646901/effect-of-ezetimibe-add-on-therapy-over-52%C3%A2-weeks-extension-analysis-of-prospective-randomized-trial-research-study-in-type-2-diabetes-subjects
#2
Kentaro Sakamoto, Mitsunobu Kawamura, Takayuki Watanabe, Keiko Ashidate, Takahide Kohro, Akira Tanaka, Yasumichi Mori, Motoki Tagami, Tsutomu Hirano, Tsutomu Yamazaki, Teruo Shiba
BACKGROUND: Lowering cholesterol levels decreases the risk of atherosclerotic diseases. Effective ways to stably reduce LDL-C level are warranted in type 2 diabetic patients, a high-risk population for CVD, with various anti-diabetic therapeutic background. The RESEARCH study focuses on LDL-C reduction in this population along with modifications of the lipid profiles. We evaluated long-term ezetimibe add-on therapy in T2DM patients with hypercholesterolemia. METHODS: In a randomized, multicenter, open-label, prospective study, a total of 109 T2DM patients not attaining LDL-C target value despite first-line dose statin (10 mg of atorvastatin or 1 mg of pitavastatin) therapy in Japan were recruited...
June 24, 2017: Lipids in Health and Disease
https://www.readbyqxmd.com/read/28644038/critical-review-on-the-analytical-techniques-for-the-determination-of-the-oldest-statin-atorvastatin-in-bulk-pharmaceutical-formulations-and-biological-fluids
#3
K S Kokilambigai, R Seetharaman, K S Lakshmi
Statins are a group of medicines that can help to lower the level of low-density-lipoprotein(LDL) cholesterol "bad cholesterol" in the blood. Having a high level of LDL cholesterol is potentially dangerous, as it can lead to a hardening and narrowing of arteries (atherosclerosis) and cardiovascular disease (CVD), Atorvastatin is one of the oldest member of the statin family and is used in the treatment of dyslipidemia and the prevention of cardiovascular disease. Atorvastatin was first made in August 1985 and from 1996 to 2012 under the trade name Lipitor, atorvastatin became the world's best selling drug...
June 23, 2017: Critical Reviews in Analytical Chemistry
https://www.readbyqxmd.com/read/28641407/efficacy-of-ezetimibe-combined-with-atorvastatin-in-treatment-of-carotid-artery-plaque-in-patients-with-type-2-diabetes-mellitus-complicated-with-coronary-heart-disease
#4
Jing Wang, Xiao-Bo Ai, Fei Wang, Yao-Wu Zou, Li Li, Xiao-Lei Yi
BACKGROUND: To evaluate the efficacy of ezetimibe combined with atorvastatin in treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease (CHD). METHODS: A total of 100 patients with carotid atherosclerosis (CAS) confirmed by ultrasound and diagnosed with type 2 diabetes mellitus and CHD were randomly assigned to atorvastatin group (atorvastatin 20 mg/d) or combined treatment group (ezetimibe 10 mg/d and atorvastatin 20 mg/d)...
June 21, 2017: International Angiology: a Journal of the International Union of Angiology
https://www.readbyqxmd.com/read/28641153/lipoprotein-a-and-coronary-atheroma-progression-rates-during-long-term-high-intensity-statin-therapy-insights-from-saturn
#5
Rishi Puri, Christie M Ballantyne, Ron C Hoogeveen, Mingyuan Shao, Philip Barter, Peter Libby, M John Chapman, Raimund Erbel, Benoit J Arsenault, Joel S Raichlen, Steven E Nissen, Stephen J Nicholls
BACKGROUND & AIMS: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL)-like particle that associates with major adverse cardiovascular events (MACE). We examined relationships between Lp(a) measurements and changes in coronary atheroma volume following long-term maximally-intensive statin therapy in coronary artery disease patients. METHODS: Study of coronary atheroma by intravascular ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) used serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months...
June 15, 2017: Atherosclerosis
https://www.readbyqxmd.com/read/28640441/adipose-tissue-derived-omentin-1-function-and-regulation
#6
Takuya Watanabe, Kaho Watanabe-Kominato, Yui Takahashi, Miho Kojima, Rena Watanabe
Omentin-1, also known as intelectin-1, is a recently identified novel adipocytokine of 313 amino acids, which is expressed in visceral (omental and epicardial) fat as well as mesothelial cells, vascular cells, airway goblet cells, small intestine, colon, ovary, and plasma. The level of omentin-1 expression in (pre)adipocytes is decreased by glucose/insulin and stimulated by fibroblast growth factor-21 and dexamethasone. Several lines of experimental evidence have shown that omentin-1 plays crucial roles in the maintenance of body metabolism and insulin sensitivity, and has anti-inflammatory, anti-atherosclerotic, and cardiovascular protective effects via AMP-activated protein kinase/Akt/nuclear factor-κB/mitogen-activated protein kinase (ERK, JNK, and p38) signaling...
June 18, 2017: Comprehensive Physiology
https://www.readbyqxmd.com/read/28636885/differential-changes-in-the-pharmacokinetics-of-statins-in-collagen-induced-arthritis-rats
#7
Chun-Han Lin, Ke-Wei Hsu, Chia-Hao Chen, Yow-Shieng Uang, Chun-Jung Lin
The elevated systemic levels of cytokines in rheumatoid arthritis (RA) can change the expression of metabolic enzymes and transporters. Given that statins are lipid-lowering agents frequently used in RA patients with concurrent cardiovascular diseases, the objective of the present study was to investigate the impacts of RA on the pharmacokinetics of statins of different disposition properties in rats with collagen-induced arthritis (CIA). The expression of metabolic enzymes and transporters in tissues of CIA rats were analyzed by RT-qPCR...
June 18, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/28636803/atorvastatin-attenuates-testosterone-induced-benign-prostatic-hyperplasia-in-rats-role-of-peroxisome-proliferator-activated-receptor-%C3%AE-and-cyclo-oxygenase-2
#8
Ismail O Ishola, Habeeb K Tijani, Olufunke O Dosumu, Charles C Anunobi, Tolulope O Oshodi
Diabetes and obesity have been reported to alter sex steroid hormone metabolism. In this study, an attempt was made to investigate the protective effect of atorvastatin (ATR) in combination with celecoxib (CEL) or pioglitazone (PIO) on testosterone-induced BPH in rats. Male Wistar rats (200-250 g) were randomly divided into 9 groups (n=8) and orally treated as follows for 28 consecutive days; Group 1: vehicle (10 ml/kg), group 2: vehicle (10 ml/kg), groups 3 - 5: ATR (0.5, 2.5 and 5 mg/kg, respectively); group 6: CEL (20 mg/kg); Group 7: PIO (20 mg/kg); Groups 8-9: ATR 0...
June 21, 2017: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/28630863/the-effects-of-melatonin-on-elevated-liver-enzymes-during-statin-treatment
#9
Cezary Chojnacki, Aleksandra Błońska, Jan Chojnacki
Taking statins can cause increase in the level of aspartate and alanine aminotransferase. The aim of this study was to assess the usefulness of melatonin in counteracting the adverse hepatic events from statins. Methods. The research program included 60 patients (aged 47-65 years, 41 women and 19 men) with hyperlipidemia taking atorvastatin or rosuvastatin at a dose of 20-40 mg daily. The patients were randomly allocated in two groups. Group I (n = 30) was recommended to take the same statin at a standardized daily dose of 20 mg together with melatonin at a dose of 2 × 5 mg...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28630772/severe-rhabdomyolysis-due-to-presumed-drug-interactions-between-atorvastatin-with-amlodipine-and-ticagrelor
#10
Iouri Banakh, Kavi Haji, Ross Kung, Sachin Gupta, Ravindranath Tiruvoipati
Atorvastatin and ticagrelor combination is a widely accepted therapy for secondary prevention of ischaemic heart disease. However, rhabdomyolysis is a well-known rare side effect of statins which should be considered when treatments are combined with cytochrome P450 3A4 enzyme inhibitors. We report a case of atorvastatin and ticagrelor associated severe rhabdomyolysis that progressed to multiorgan failure requiring renal replacement therapy, inotropes, intubation, and mechanical ventilation. Despite withdrawal of the precipitating cause and the supportive measures including renal replacement therapy, creatinine kinase increased due to ongoing rhabdomyolysis rapidly progressing to upper and lower limbs weakness...
2017: Case Reports in Critical Care
https://www.readbyqxmd.com/read/28628347/preventive-treatment-with-atorvastatin-ameliorates-endothelial-dysfunction-of-small-pulmonary-arteries-in-monocrotaline-induced-pulmonary-hypertensive-rats
#11
Zhihong Lin, Zhi Jiang, Xiaodong Huang, Xiaoqi Cai, Huajun Wang, Liangdi Xie
This study examined the effects of preventive atorvastatin (Ator) treatment on vasodilatation of small pulmonary arteries (SPAs) in monocrotaline (MCT)-induced pulmonary hypertensive rats. SD rats were randomly assigned to: normal control (Ctr), pulmonary arterial hypertension (PAH), PAH treated with 5 mg/kg/d Ator (LAtor), or 10 mg/kg/d Ator (HAtor). PAH was induced by MCT injection (40 mg/kg, i.p.). Mean pulmonary artery pressure (mPAP), right ventricular hypertrophy index (RVHI%), endothelium-dependent relaxations (EDdRs), and endothelium-independent relaxations (EDiRs) were determined...
June 19, 2017: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/28628040/lipogenic-transcription-factor-chrebp-mediates-fructose-induced-metabolic-adaptations-to-prevent-hepatotoxicity
#12
Deqiang Q Zhang, Xin Tong, Kyle VanDommelen, Neil Gupta, Kenneth Stamper, Graham F Brady, Zhuoxian Meng, Jiandie D Lin, Liangyou Y Rui, M Bishr Omary, Lei Yin
Epidemiologic and animal studies implicate overconsumption of fructose in the development of nonalcoholic fatty liver disease, but the molecular mechanisms underlying fructose-induced chronic liver diseases remain largely unknown. Here, we have presented evidence supporting the essential function of the lipogenic transcription factor carbohydrate response element-binding protein (ChREBP) in mediating adaptive responses to fructose and protecting against fructose-induced hepatotoxicity. In WT mice, a high-fructose diet (HFrD) activated hepatic lipogenesis in a ChREBP-dependent manner; however, in Chrebp-KO mice, a HFrD induced steatohepatitis...
June 19, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28626049/dose-dependent-effect-of-statin-pretreatment-on-preventing-the-periprocedural-complications-of-carotid-artery-stenting
#13
Jeong-Ho Hong, Sung-Il Sohn, Jaehyuk Kwak, Joonsang Yoo, Hyuk Won Chang, O-Ki Kwon, Cheolkyu Jung, Inyoung Chung, Hee-Joon Bae, Ji Sung Lee, Moon-Ku Han
BACKGROUND AND PURPOSE: We investigated whether statin pretreatment can dose dependently reduce periprocedural complications in patients undergoing carotid artery stenting because of symptomatic carotid artery stenosis. METHODS: We enrolled a consecutive series of 397 symptomatic carotid artery stenosis (≥50% stenosis on conventional angiography) treated with carotid artery stenting at 2 tertiary university hospitals over a decade. Definition of periprocedural complications included any stroke, myocardial infarction, and death within 1 month after or during the procedure...
June 16, 2017: Stroke; a Journal of Cerebral Circulation
https://www.readbyqxmd.com/read/28625961/effect-of-atorvastatin-on-lower-extremity-function-of-patients-with-hypertension-and-peripheral-arterial-disease
#14
Kewei Zhang, Shuiting Zhai, Kun Li, Zhidong Zhang, Kun Li, Tianxiao Li
This paper aims to discuss the short-term effect of Atorvastatin on lower-extremity function of patients with hypertension and peripheral arterial disease (PAD). 40 patients with hypertension and ankle-brachial index (ABI) less than 0.9 were divided into the control group (20 cases) and Atorvastatin group (20 cases) and treated for 6 months. The variation between the 6-min walk and the gait speed of 4-m-walk before and after the treatment were respectively observed. With regard to the two groups, differences of the drop-out values before and after the treatment were adjusted in accordance with gender, ages, body mass index (BMI), difference values of systolic pressure, ABI, difference values of total cholesterol (TC), difference values of low density lipoprotein, triacylglycerol, smoking and drug-taking situation...
January 2017: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28623954/efficacy-and-safety-of-alirocumab-in-patients-with-hypercholesterolemia-not-adequately-controlled-with-non-statin-lipid-lowering-therapy-or-the-lowest-strength-of-statin-odyssey-nippon-study-design-and-rationale
#15
Tamio Teramoto, Akira Kondo, Arihiro Kiyosue, Mariko Harada-Shiba, Yasushi Ishigaki, Kimimasa Tobita, Yumiko Kawabata, Asuka Ozaki, Marie T Baccara-Dinet, Masataka Sata
BACKGROUND: Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), which can produce substantial and sustained reductions of low-density lipoprotein cholesterol (LDL-C). METHODS: The randomized, double-blind, placebo-controlled, parallel-group, phase 3 ODYSSEY NIPPON study will explore alirocumab 150 mg every 4 weeks (Q4W) in 163 Japanese patients with hypercholesterolemia who are on the lowest-strength dose of atorvastatin (5 mg/day) or are receiving a non-statin lipid-lowering therapy (LLT) (fenofibrate, bezafibrate, ezetimibe, or diet therapy alone)...
June 17, 2017: Lipids in Health and Disease
https://www.readbyqxmd.com/read/28622167/statin-and-its-association-with-delirium-in-the-medical-icu
#16
Jeffrey F Mather, John P Corradi, Christine Waszynski, Adam Noyes, Yinghui Duan, James Grady, Robert Dicks
OBJECTIVES: To examine the association between statin use and the risk of delirium in hospitalized patients with an admission to the medical ICU. DESIGN: Retrospective propensity-matched cohort analysis with accrual from September 1, 2012, to September 30, 2015. SETTING: Hartford Hospital, Hartford, CT. PATIENTS: An initial population of patients with an admission to a medical ICU totaling 10,216 visits were screened for delirium by means of the Confusion Assessment Method...
June 15, 2017: Critical Care Medicine
https://www.readbyqxmd.com/read/28620871/lipophilic-statins-and-the-risk-of-intracranial-hemorrhage-following-ischemic-stroke-a-population-based-study
#17
Kieran L Quinn, Erin M Macdonald, Muhammad M Mamdani, Christina Diong, David N Juurlink
BACKGROUND: Statins are commonly prescribed for the secondary prevention of ischemic stroke, but there is conflicting evidence as to whether they increase the risk of intracranial hemorrhage. Lipophilic statins cross the blood-brain barrier more freely than hydrophilic statins and may therefore increase the risk of intracranial hemorrhage. OBJECTIVE: To determine whether, in older patients following ischemic stroke, receipt of lipophilic statins was associated with differences in the risk of intracranial hemorrhage...
June 15, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/28620818/effects-of-atorvastatin-and-simvastatin-on-oxidative-stress-in-diet-induced-hyperhomocysteinemia-in-wistar-albino-rats-a-comparative-study
#18
T Nikolic, V Zivkovic, I Srejovic, I Stojic, N Jeremic, J Jeremic, K Radonjic, S Stankovic, R Obrenovic, D Djuric, V Jakovljevic
Considering the well-known antioxidant properties of statins, it seems important to assess their impact on major markers of oxidative stress (superoxide anion radical, nitric oxide, and index of lipid peroxidation) to compare the antioxidative potentials of atorvastatin and simvastatin during the different degrees of hyperhomocysteinemia (HHcy) in rats. This study was conducted on adult male Wistar albino rats (n = 90; 4 weeks old; 100 ± 15 g body mass) in which HHcy was achieved by dietary manipulation...
June 15, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28619533/-dyslipidemia-management-in-patients-with-high-cardiovascular-risk-in-spain-alma-study
#19
Xavier Pintó, Ferran Trias Vilagut, Joan Rius Taruella, Esther Mairal Sallán
OBJECTIVE: To assess the attitude of primary care (PCPs) and specialized care (SCPs) physicians towards the general set of patients with dyslipidemia, particularly those with cardiovascular risk factors. DESIGN: Observational, descriptive, multi-center study based on a survey. LOCATION: Different healthcare regions in Spain. PARTICIPANTS: 1,402 PCPs, and 596 SCPs. MAIN MEASUREMENTS: Physician's profile, routine practices in the management of patients with dyslipidemia...
June 12, 2017: Atencion Primaria
https://www.readbyqxmd.com/read/28617150/atorvastatin-loaded-nanostructured-lipid-carriers-nlcs-strategy-to-overcome-oral-delivery-drawbacks
#20
Mohammed Elmowafy, Hany M Ibrahim, Mohammed A Ahmed, Khaled Shalaby, Ayman Salama, Hossam Hefesha
Atorvastatin (AT) is a widely used lipid-regulating drug to reduce cholesterol and triglycerides. Its poor aqueous solubility and hepatic metabolism require development of drug delivery systems able to improve its solubility and bypass hepatic effect. For this purpose, atorvastatin nanostructured lipid carriers (AT-NLCs) were prepared and characterized. AT-NLCs were prepared by emulsification using high-speed homogenization followed by ultrasonication. The prepared NLCs showed particle size between 162.5 ± 12 and 865...
November 2017: Drug Delivery
keyword
keyword
6831
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"